Search company, investor...

Executives

17

Board of Directors

5

ViewRay Management Team

17 Team Members

ViewRay has 17 executives. ViewRay's founder is Russ Donda. ViewRay's is .

Name

Work History

Title

Status

Russ Donda

BioEnterprise, HyGreen, Synogen Development Group, and RTI Surgical

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Russ Donda

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

BioEnterprise, HyGreen, Synogen Development Group, and RTI Surgical

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

ViewRay Board of Directors

5 Board of directors

ViewRay has 5 board of directors, including Brian Roberts.

Name

Firm

Work History

Other Seats

Brian Roberts

ViewRay

Caley Castelein

Caley is a founder and managing member of Kearny Venture Partners and KVP Capital. Caley is a current board member of Alivecor, Boreal, Newbridge Pharmaceuticals, ViewRay, WellPartner, and Waterstone Pharmaceuticals. At Kearny, his previous investments include Aspreva (acquired by Gelenica), CoTherix (acquired by Actelion), Kai (acquired by Amgen), Roxro (acquired by a unit of Daiichi Sankyo), and QuatRx (partnered with Shionogi). Caley received his M.D. from the University of California, San Francisco, with honors. During medical school, he ran a research program investigating the genetic causes of deafness and the application of gene therapy to treatment of hearing loss. The findings were published in leading journals including Nature Genetics. After medical school, Caley completed a general surgery internship at the University of California, San Francisco. He received an A.B. magna cum laude from Harvard College.

ViewRay

David Bonita

David Bonita, M.D., has been a member of Prelude’s Board of Directors since July 2016. Since June 2014, Dr. Bonita has served in various roles at OrbiMed Advisors LLC. Dr. Bonita currently serves on the boards of directors of a number of public and private companies. He has also worked as a Corporate Finance Analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.

ViewRay

Joshua Bilenker

Josh Bilenker is the co-founder and Chief Executive Officer of Treeline Biosciences. Previously, he was the CEO of Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company. Dr. Bilenker joined Eli Lilly in 2019 after it acquired his prior company, Loxo Oncology, Inc. From 2006 to 2013, Dr. Bilenker worked as a life sciences venture capital investor at Aisling Capital LLC. From 2004 to 2006, Dr. Bilenker served as a medical officer at the US Food and Drug Administration, in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins University School of Medicine and his A.B. degree in English from Princeton University.

ViewRay

Robert Weisskoff

Robert Weisskoff, Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents. Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa. Robert serves on the Board of Directors of Adela, CORE Diagnostics, Plasmagen Biosciences, RareCyte, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Caribou Biosciences (NASDAQ: CRBU), Farapulse (acquired by Boston Scientific), Ikano Therapeutics (acquired by UCB), Laurus Labs (NSE:LAURUSLABS), Structure Therapeutics (NASDAQ:GPCR), Surface Oncology (NASDAQ:SURF), Tetraphase (NASDAQ:TTPH), Transave (NASDAQ:INSM), Topaz (acquired by Sanofi Pasteur), ViewRay (NASDAQ:VRAY) and Xilio Therapeutics (NASDAQ: XLO).

ViewRay

Name

Brian Roberts

Caley Castelein

David Bonita

Joshua Bilenker

Robert Weisskoff

Firm

Work History

Caley is a founder and managing member of Kearny Venture Partners and KVP Capital. Caley is a current board member of Alivecor, Boreal, Newbridge Pharmaceuticals, ViewRay, WellPartner, and Waterstone Pharmaceuticals. At Kearny, his previous investments include Aspreva (acquired by Gelenica), CoTherix (acquired by Actelion), Kai (acquired by Amgen), Roxro (acquired by a unit of Daiichi Sankyo), and QuatRx (partnered with Shionogi). Caley received his M.D. from the University of California, San Francisco, with honors. During medical school, he ran a research program investigating the genetic causes of deafness and the application of gene therapy to treatment of hearing loss. The findings were published in leading journals including Nature Genetics. After medical school, Caley completed a general surgery internship at the University of California, San Francisco. He received an A.B. magna cum laude from Harvard College.

David Bonita, M.D., has been a member of Prelude’s Board of Directors since July 2016. Since June 2014, Dr. Bonita has served in various roles at OrbiMed Advisors LLC. Dr. Bonita currently serves on the boards of directors of a number of public and private companies. He has also worked as a Corporate Finance Analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.

Josh Bilenker is the co-founder and Chief Executive Officer of Treeline Biosciences. Previously, he was the CEO of Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company. Dr. Bilenker joined Eli Lilly in 2019 after it acquired his prior company, Loxo Oncology, Inc. From 2006 to 2013, Dr. Bilenker worked as a life sciences venture capital investor at Aisling Capital LLC. From 2004 to 2006, Dr. Bilenker served as a medical officer at the US Food and Drug Administration, in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins University School of Medicine and his A.B. degree in English from Princeton University.

Robert Weisskoff, Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents. Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa. Robert serves on the Board of Directors of Adela, CORE Diagnostics, Plasmagen Biosciences, RareCyte, and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Caribou Biosciences (NASDAQ: CRBU), Farapulse (acquired by Boston Scientific), Ikano Therapeutics (acquired by UCB), Laurus Labs (NSE:LAURUSLABS), Structure Therapeutics (NASDAQ:GPCR), Surface Oncology (NASDAQ:SURF), Tetraphase (NASDAQ:TTPH), Transave (NASDAQ:INSM), Topaz (acquired by Sanofi Pasteur), ViewRay (NASDAQ:VRAY) and Xilio Therapeutics (NASDAQ: XLO).

Other Seats

ViewRay

ViewRay

ViewRay

ViewRay

ViewRay

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare ViewRay to Competitors

C
Calpyso Medical

Calypso Medical provides technologies in the radiation oncology market

R
Radiation Shield Technologies

Radiation Shield Technologies specializes in the research, design, and production of personal protection systems within the safety and defense industry. The company offers products such as full body suits, blankets, and tents made from a patented, lightweight, non-toxic, and lead-free fabric called Demron, which is designed to protect individuals from ionizing and nuclear radiation. These products are aimed at providing safety for users in environments where radiological or nuclear hazards are present. It is based in Coral Gables, Florida.

Smart Animal Logo
Smart Animal

Smart Animal is a research company focused on personalized medicine within the immunotherapy and diagnostics sectors. They offer a platform-oriented device that modifies or enhances the body's immune response to target diseases, administered in outpatient settings. The company's technology is used for labeling antibodies for imaging and targeted drug delivery in cancer treatment and can be applied to autoimmune disorders and veterinary use. It was founded in 2006 and is based in Marlborough, Massachusetts.

CivaTech Oncology Logo
CivaTech Oncology

Civatech Oncology is a medical device company focused on the development of polymer-based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for the encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy. CivaTech Oncology was founded in 2006 and is based in Durham, North Carolina.

I
InnerOptic

InnerOptic Technology, Inc. specializes in augmented reality and image guidance systems for the medical sector. The company offers FDA-cleared 3D navigation tools designed to enhance the precision and safety of medical procedures. These products are primarily utilized in the healthcare industry to assist with interventions such as needle navigation and surgical procedures. It is based in Hillsborough, North Carolina.

HyperMed Imaging Logo
HyperMed Imaging

HyperMed Imaging is a company focused on medical hyperspectral imaging within the healthcare industry. The company's main offering is advanced portable imaging technology that assesses oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue, providing key information for various healthcare applications. The primary sector HyperMed Imaging serves is the healthcare industry, specifically in areas requiring quick and efficient determination of surface tissue oxygenation. It was founded in 1997 and is based in Memphis, Tennessee.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.